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A B S T R A C T   
Background: The aim of this study was to determine the impact of COVID-19 pandemic on the total testing 
process using six sigma metrics based on a comparison of pre and during pandemic periods. 
Material & methods: The study duration was over 12 months, 6 months before and 6 months after the COVID-19 
onset in Pakistan in March 2020 after the recognition of the first case, using quality indicators (QIs). QIs were 
chosen from a model of QIs recommended by the CAP. Analysis was performed using Six Sigma calculators and 
QIs were expressed in percentage (%) and Sigma value were computed. Three levels of performance quality i.e. 
25th, 50th, and 75th percentile were derived, being best, common and worst performance respectively. Between- 
group differences were tested using the Mann-Whitney’s U test. 
Results: The median defect percentages of these QIs ranged from 0% to 0.27% for the pre-pandemic period and 
0% to 0.13% for the during pandemic period. Meanwhile, sigma values of the majority of the QIs were all above 
4.0σ during the pre and the pandemic times. For the pre-analytical phase, sigma scores declined for 1 QI, 
improved for 3 QIs and remained same for 2. In the post analytical phase, no change in sigma metrics was noted 
for critical values notification. Considerable increase in defect percentage of inappropriate turnaround times was 
noted. 
Conclusion: The emergency preparedness proved to be fruitful as depicted by exceptional performance on the 
sigma metrics for most Qis both prior to and during the pandemic. The pre-analytical and the post analytical 
phases, being the most error sensitive requires strict vigilance.   
1. Introduction 
The Corona virus disease 2019 (COVID-19) pandemic affected 
almost every nation across the globe, impacting more than 20 million 
lives alongside services and economic productivity [1]. The pandemic 
triggered an unexpected global emergency which has had huge impact 
on many organizations including health structure, health care pro-
fessionals and clinical laboratories [2]. The part played by laboratory 
medicine during a pandemic has been widely recognized [3]. A 
comprehensive summary of previous researches strengthens the fact that 
the diagnosis of COVID-19 would not have been possible without the 
laboratory services, either by detecting the pathogen through reverse 
transcriptase-polymerase chain reaction (RT-PCR), or quantifying anti-
body response via immunological based techniques [4]. Hence, 
laboratories have a crucial part to play during an infectious outspread 
from the time of diagnosis till surveillance. 
While the pandemic has highlighted the significance of laboratory 
medicine in healthcare setups, laboratory testing is altogether an intri-
cate process [5]. Each of the various steps involved total testing process 
can result in errors and they can have a huge impact on patient prognosis 
[6]. In laboratory practice, total testing process is divided into three 
crucial steps: pre-analytical, analytical and post-analytical [7]. Quality 
indicators are considered as the fundamental tools of maintaining 
quality in laboratory systems that can be gauged to assess each step of 
total testing process. The utilization of quality indicators in clinical 
laboratory allows determining error incidence and diminishing or 
arresting patient safety errors [8]. 
This COVID-19 pandemic has clearly exhausted the laboratories 
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resources with obstacles such as shortage of staff, conveyance issues, 
short supply of personal protective equipment (PPE), delayed shipments 
of necessities, and particularly, fear and anxiety amongst healthcare 
workers. The preparations to tackle such crises are never mentioned in 
the books of laboratories especially for resource constrained setups in 
developing world. 
During the ongoing pandemic, the healthcare professionals were 
made to follow additional caution and wear recommended PPE. 
Accreditation and regulatory bodies are increasingly emphasizing lab-
oratories to go beyond analytical quality and focus on the pre- and post- 
analytical phases, where most errors arise that can influence clinical 
care. Furthermore, the specimen collection and transport logistics were 
also considerably unalike from the pre-pandemic times [7,8]. The 
impact of these changed protocols for specimen collection, packaging 
and transport on the total testing process is not widely established. The 
purpose of this study was to determine the impact of COVID-19 
pandemic on the pre and post analytical testing process using six 
sigma metrics based on a comparison of pre and pandemic periods. 
2. Material & Methods 
This retrospective observational study was conducted at the Section 
of Clinical Chemistry, Department of Pathology and Laboratory Medi-
cine at Aga Khan University Hospital (AKUH), Karachi, Pakistan. The 
clinical laboratory is the largest reference laboratory catering a country 
wide population of 240 million with its growing network of more than 
280 phlebotomy stations and stat laboratories spread across Pakistan. 
The laboratory operates to highest standards of quality and was the first 
to be accredited by Joint Commission International Accreditation (JCIA) 
and the only lab with College of American Pathologist (CAP) accredi-
tation in Pakistan. 
This study was done to evaluate the repercussions of the pandemic 
on the quality of the test process. The study duration was 12 months, 6 
months before and 6 months following the COVID-19 onset in Pakistan 
in March 2020 after the recognition of the first case, using Q6 Is. Data 
was retrospectively retrieved from the electronic laboratory information 
management system. At our center, the preanalytical, analytical, and 
postanalytical processes are regularly monitored and recorded using QIs 
and presented in monthly departmental quality management committee 
meeting for appropriate actions if necessary. Quality indicators were 
chosen from a model of QIs recommended by the CAP [9]. QIs were 
categorized in accordance with the main TTP phases as shown in 
Table 1. 
Analysis was performed using Six Sigma calculators and QIs were 
expressed in percentage (%) and sigma value were computed [10]. 
Three levels of performance quality i.e., 25th, 50th, and 75th percentile 
was derived, being best, common and worst performance respectively as 
described previously by Sciacovelli L et al. [11]. Between-group differ-
ences were tested using the Mann-Whitney’s U test taking a p-value of 
<0.05 as statistically significant difference. The Statistical Package for 
Social Sciences (SPSS) software program (v.22; IBM, Armonk, NY) and a 
P < 0.05 was considered as statistically significant for all analyses. This 
work has been reported in line with the STROCSS criteria [12]. 
3. Results 
A total of 2,528,589 specimens were screened of which 999,437 
(40%) were received during the pandemic phase. A total of 30,926 
critical results were informed out of which 12,118 (39%) were during 
the pandemic phase. Moreover, 214,884 stat results were processed of 
which 83,065 (39%) were during the pandemic period. The error rates 
for all QIs were regularly monitored, against established benchmarks, 
adopted from the Q-Probes and Q-Tracks studies from CAP. A review of 
the records revealed that all the Qis were well within the respective 
benchmarks [13]. 
Defect percentages and sigma values related to pre-analytical, 
analytical and post-analytical phase are depicted in Table 1. The me-
dian defect percentages of these QIs ranged from 0% (leaking con-
tainers) to 0.27% (manual labeling, without barcode) for the pre- 
pandemic period and 0% (leaking containers) to 0.13% (without 
Table 1 
QIs representing pre and post analytical phase from pre- and during pandemic periods.   
Quality Indicators Period Defect percentage (%) Sigma values p- 
value 




Percentage of number of hemolyzed samples/total number of samples Pre-pandemic 0.05 0.05 0.06 4.8 4.7 4.7 0.16 
During 
pandemic 
0.05 0.06 0.06 4.7 4.7 4.7          
Percentage of number of QNS samples/total number of samples Pre-pandemic 0.01 0.02 0.02 5 5 4.9 1.00 
During 
pandemic 
0.01 0.01 0.02 5 4.9 5.1          
Percentage of number of empty container/total number of samples Pre-pandemic 0 0 0 6 6 6 0.93 
During 
pandemic 
0 0 0 6 6 6          
Percentage of number of bad barcode samples/total number of 
samples 
Pre-pandemic 0 0 0.01 5 4.9 4.4 0.81 
During 
pandemic 
0.005 0.03 0.04 4.6 4.7 4.5          
Percentage of number of without barcode sample/total number of 
samples 
Pre-pandemic 0.16 0.23 0.27 4.5 4.4 4.3 0.87 
During 
pandemic 
0.07 0.1 0.13 4.7 4.6 4.4          
Percentage of number of leaking container/total number of samples Pre-pandemic 0 0 0 6 6 6 0.93 
During 
pandemic 




Percentage of number of critical results informed within time/total 
number of samples 
Pre-pandemic 0 0 0 6 6 6 0.93 
During 
pandemic 
0 0 0 6 6 6          
Percentage of number of STAT samples/total number of samples Pre-pandemic 0.003 0.003 0.004 4.4 4.5 4.3 0.37 
During 
pandemic 
0.006 0.008 0.009 4.4 4.4 4.6  
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barcode samples) for the during pandemic period. The QIs were moni-
tored through rigorous and vigilant practices at the receiving and pro-
cessing bench housed by a team of technologists led by a charge 
technologist. As correct patient identification and correct specimen la-
beling are recognized cardinal safety goals by CAP, without barcode 
samples with manual entries were visually scanned and segregated. The 
entries were re-verified from the test requisition slips and barcodes 
generated and applied for optimal further processing and analysis. 
For the 1 QI (bad barcode samples) defect percentages increased with 
a decrement in sigma values during the pandemic compared to the pre- 
pandemic phase. On the contrary, sigma metrics improved, and defect 
percentages went down for 2 QIs (number of insufficient quantity (QNS) 
samples, number of without barcode samples). Whereas sigma values for 
3 QIs (hemolyzed samples, leaking containers, empty containers) were 
almost the same before and during the pandemic. 
Amongst the 2 QIs related to the post analytical phase, no change in 
sigma metrics was noted for critical values notification. While there was 
a considerable increase in defect percentage of inappropriate turn-
around times with lower sigma scores compared to the pre pandemic era 
as depicted in Table 1. However, as the difference between the pandemic 
and pre pandemic era was not significant, the p-values calculated were 
not statistically significant. Meanwhile, sigma values of the majority of 
the QIs were all above 4.0σ before and after the onset of the pandemic as 
depicted by the graphical trends in Fig. 1. 
4. Discussion 
This study is the first to assess the impact of the pandemic on the 
testing processes at a high-volume clinical chemistry laboratory in 
Pakistan, a lower middle-income country hardest hit by the pandemic. 
The sudden rise in cases, increasing demands of prognostic biomarkers 
including ferritin, lactate dehydrogenase, procalcitonin, interleukin-6 
and c-reactive protein and different coping strategies adopted, led to 
enhanced workload and pressure on laboratory staff, making them 
prone to errors [14,15]. As anticipated, a mixed trend was noted for the 
QIs on comparison between the pre and during pandemic phases, with 
improvements in some areas to regression in others. 
From a laboratorian’s perspective, the pre-analytical errors account 
for up to 70% of all mistakes made in laboratory diagnostics [16]. It is 
this phase that can highly influence the test results in turn impacting 
medical decisions. However, in this study only one QI belonging to the 
pre-analytical phase showed a decline whereas the sigma scores for the 
others QIs either remained unchanged or showed an improving trend. 
Our results are in contrast to Tapasyapreeti M et al., who have reported 
that preanalytical errors and resultant blood specimen rejection rate at a 
clinical laboratory in India have significantly increased due to changed 
logistics [17]. This comparison substantiates the impact of contingency 
measures taken by our laboratory to facilitate logistics and staff short-
ages managed appropriately even during the strict lock down period, 
that prevented any major decline in the sigma scores in this vulnerable 
pandemic phase. 
In the post analytical phase, the critical result reporting maintained 
the sigma benchmark of the pre-pandemic era. However, few stat delays 
were encountered during the pandemic phase. Our findings are in 
contrast with Eren F et al. and colleagues who have reported high per-
centage of critical reporting delays during the pandemic at a clinical 
laboratory in Ankara [18]. The few instances of stat delays were linked 
with delayed specimen transport from clinical care areas, which may be 
related to staff shortages. 
There were certain limitations of our study, notably more than 15 QIs 
could be used to evaluate the testing processes, however the most sig-
nificant ones that can impact lab performances were examined in this 
study. Moreover, the performance of external quality assessments and 
proficiency testing was not assessed on the sigma metrics, because of the 
difference in time intervals of different surveys which may influence 
sigma calculations. 
5. Conclusion 
Identification of lab errors, rectification and vigilance serve as pillars 
of total quality management. The emergency preparedness and strate-
gies adopted amidst the crisis situation proved to be fruitful as depicted 
by exceptional performance on the sigma metrics for most QIs in the 
high-volume reference laboratory in Pakistan. The pre-analytical and 
the post-analytical phases, being the most error sensitive requires strict 
vigilance to maintain good quality assurance in a clinical laboratory. 
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Fig. 1. Sigma trend of quality indicators.  
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